Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Pilot Cohort Study to Investigate the Safety and Efficacy of Infliximab as Additional Therapy in the Treatment if Anti-Neutrophil Cytoplasm Antibody Associated Vasculitis

NCT00753103 is registered in ClinicalTrials.gov with University Hospital Birmingham NHS Foundation Trust as lead sponsor.

NCT NCT00753103
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00753103 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Pilot Cohort Study to Investigate the Safety and Efficacy of Infliximab as Additional Therapy in the Treatment if Anti-Neutrophil Cytoplasm Antibody Associated Vasculitis
Lead sponsor
University Hospital Birmingham NHS Foundation Trust
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2003
Completion date
July 31, 2006
Enrollment
37 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

microscopic polyangiitis, renal limited vasculitis, wegener's granulomatosis